82 results about "Vascular proliferation" patented technology

Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.

Compounds represented by the following structure (II) are disclosed:as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.

Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.

A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of lysine-plasminogen, at least one recombinant plasminogen activator selected from the group consisting of urokinase, streptokinase, tissue plasminogen activator, chondroitinase, pro-urokinase, retavase, metaloproteinase, and thermolysin and a gaseous adjuvant to form a cavity in the vitreous. The composition is introduced into the vitreous in an amount effective to induce crosslinking of the vitreous and to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment.

Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1′, R1″, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.

The invention relates to use of microbubbles with high-intensity cavitation generated by combining ultrasonic in preparation of anti-tumor neovascularization medicaments. The microbubbles are high-intensity cavitation effect microbubbles generating mechanical damage under the action of pulse-type high-peak negative pressure ultrasonic energy; and the ultrasonic energy has higher peak sound pressure and lower transmitting duty cycle. The generated high-intensity cavitation effect can generate obvious tumor microcirculation blocking effect on the tumor neovascularization, repeatedly perform deprivation therapy for further generating tumor growth inhibition, and reduce the transfer rate of malignant tumors. The novel treatment use of the microbubbles is applied to the treatment of various solid malignant tumors and angiogenesis pathological changes and is brand new use of the microbubble with application prospect.

The invention discloses a medicine combination containing fusion protein for suppressing angiogenesis and application, and particularly relates to a medicine combination containing fusion protein of an extracellular protein domain 2 (Flt-2) of a vascular endothelial growth factor (VEGF) receptor 1, extracellular protein domains 3 and 4 (KDR-3 and 4) of a VEGF receptor 2 and human normal immunoglobulin 1(G1) Fc. The medicine combination can keep the fusion protein stable, has the most outstanding advantage of capability of effectively suppressing fusion protein polymer so as to avoid reduction of purity, and accordingly keeps bioactivity of effective components.

The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution.

The invention discloses a medicament for treating neovascularization diseases. The medicament employs miRNA-132 and miRNA-155 as targets and two specific antagomirs, antagomir-132 and antagomir-155, as the basic components. The above two micronucleus acids are knocked down in a lesion at the same time, so as to inhibit excessive proliferation of new vessels to achieve therapeutic effect. To ensure the effective application of the drug, the invention adopts in vivo delivery vectors, such as a histidine-lysine polypeptide polymer HKP and a ligand targeted delivery nanoparticle system RGD-PEG-HKP, in order to improve the specificity and efficiency of medicament delivered into angiogenesis sites (eye or tumor).

The invention discloses 3,4-dihydro-4-aryl coumarin derivatives as well as a preparation method and application thereof. The preparation method comprises the following steps of: with substituted benzaldehyde and malonic acid as raw materials, heating in the presence of pyridine and piperidine and generating a Perkin reaction and a decarboxylic reaction to obtain substituted phenylacrylic acid derivatives; and then subjecting the substituted phenylacrylic acid derivatives and phenol compounds to a reaction in the presence of the catalysis of boron trifluoride diethyl ether and phosphorus oxychloride to obtain the 3,4-dihydro-4-aryl coumarin compounds. The compounds can be used for preparing medicaments for resisting tumors, abnormal vascular proliferation, bacterial and oxidation.

The subject invention provides a method and compositions for preventing and / or treating abnormal vascular proliferation in a human infant where the method involves enterally administering arginine and glutamine to the infant in about equimolar amounts to provide a total amount of arginine and glutamine that is effective to prevent or treat the abnormal vascular proliferation. Arginyl-glutamine dipeptide was shown to be an advantageous form in which to provide the two amino acids.

The invention belongs to the field of antibody drug, and discloses a full human-derived anti-human VEGFR2 monoclonal antibody screened by a phage antibody base technology and prepared by a gene engineering method, and further discloses a carrier including polynucleotide for encoding the monoclonal antibody, a host cell and an application. Through combining with VEGFR2, the monoclonal antibody stops the combination of VEGF with VEGR2, and does not induce receptor dimerization, cause the following tyrosine residue phosphorylation in intracellular tyrosine kinase structure and activate downstream signal access including activation of phospholipase C and increase of calcium ion concentration in the cell and others; the antibody drug triggers endothelial proliferation, survival, cytoskeleton rearrangement, cell migration, gene expression and others, and finally stops the vascular proliferation caused by combination of VEGF and VEGFR2 and induction of dimerization. The monoclonal antibody can be used for treating diseases caused by tumor angiogenesis.

The present invention relates to a method of treating vascular proliferation in a patient in need thereof. The method includes the step of administering a therapeutically effective amount of a type-1 somatostatin agonist to said patient.

The present invention discloses a Tat PTD-Endostatin recombination protein, which is a fusion protein comprising a protein transduction domain of human immunodeficiency virus (HIV) transactivation transduction protein Tat and human endostatin, wherein the amino acid sequence of the protein transduction domain of the HIV transactivation transduction protein Tat is represented by SEQ ID NO.1, and the amino acid sequence of the human endostatin is represented by SEQ ID NO.2. The protein of the present invention has the following advantages that: the function of the endostatin can be maintained, wherein the function of the endostatin is that the endostatin can inhibit angiogenesis; the protein has advantages of high transduction efficiency, easy blood-brain barrier crossing, and easy blood-ocular barrier crossing; the protein can overcome the limitation of the poor membrane spanning effect of the endostatin and play the angiogenesis inhibition effect well; the protein can be used for treatments of various diseases caused by angiogenesis, including ocular vascular proliferative diseases and various tumors, such as diabetes retinopathy, non-small cell lung cancer, and the like.

The invention discloses a medicine combination containing fusion protein for suppressing angiogenesis and application, and particularly relates to a medicine combination containing fusion protein of an extracellular protein domain 2 (Flt-2) of a vascular endothelial growth factor (VEGF) receptor 1, extracellular protein domains 3 and 4 (KDR-3 and 4) of a VEGF receptor 2 and human normal immunoglobulin 1(G1) Fc. The medicine combination can keep the fusion protein stable, has the most outstanding advantage of capability of effectively suppressing fusion protein polymer so as to avoid reduction of purity, and accordingly keeps bioactivity of effective components.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The invention discloses a formula for an anti-allergy anti-radiation anti-oxidation lotion used in spring. The formula comprises, by mass, 70 to 80 parts of lavender hydrolat, 5 to 6 parts of chamomile extract, 5 to 6 parts of aloe extract, 2 to 2.3 parts of PGD, 10 to 11 parts of hyaluronic acid, 5 to 6 parts of glycerin, 10 to 11 parts of grape seed oil, 3 to 3.4 parts of an antibacterial agent and 1 to 1.1 parts of an emulsifier. Chamomile has good effects on relieving allergy, repairing sensitive skin, decreasing fine and red blood streaks, reducing the phenomenon of redness, adjusting uneven skin tone and the like and is rich in flavonoid active components which are capable of resisting oxidation, vascular proliferation, allergy, bacteria and viruses and eliminating inflammations; aloe is capable of eliminating inflammations, resisting bacteria, enhancing skin elasticity, protecting skin mucosas, preventing acne, freckles and wrinkles, cleaning the skin, inhibiting seborrhea, preventing supurative dermatopathy and skin ageing, etc.

The invention relates to an application of oligopeptide FpAT or pharmacy acceptable salt with the amino acid sequences shown by Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg to the preparation of medicine for preventing and / or treating ophthalmic diseases relevant to angiogenesis. The medicine prepared from the oligopeptide FpAT has the advantages of good curative effect and high safety on ophthalmic diseases relevant to angiogenesis, particularly on diseases relevant to CNV (choroidal neovascularization). In addition, because the chemical ingredients are polypeptide, the preparation technology is mature, the medication cost is low, and the oligopeptide is very suitable for clinic use or popularization.

The invention belongs to the field of pharmaceuticals and relates to application of a compound radix salviae miltiorrhizae preparation to preparation of pulmonary arterial hypertension resisting medicaments. According to the application disclosed by the invention, monocrotaline and a low-pressure oxygen cabin are utilized for reproducing a pulmonary arterial hypertension model on a rat, treatment and administration are performed through compound radix salviae miltiorrhizae dripping pills, and experimental data indicates that the compound radix salviae miltiorrhizae can significantly reduce the pulmonary arterial hypertension of a model animal, show a good effect of resisting pulmonary arterial vascular proliferation in pathology and improve the pulmonary arterial ring relaxation of the animal with the pulmonary arterial hypertension. The compound radix salviae miltiorrhizae dripping pills can be used as an ideal medicament for preventing and treating the pulmonary arterial hypertension and other related diseases.

The invention discloses application of brazilin in preparation of products for prevention, mitigation and / or treatment of diseases related to protein tyrosine kinase activity abnormal increase and vascular proliferation. Brazilin has the effects of inhibiting protein tyrosine kinase (PTKs) activity and inhibiting proliferation and migration of the rat thoracic aortic vascular smooth muscle cell (VSMC). Brazilin can prevent, mitigate and / or treat PTKs activity abnormal increase related diseases like tumors, restenosis after percutaneous coronary intervention (PCI), atherosclerosis, high blood pressure, multiple sclerosis, diabetic retinopathy, endometriosis, psoriasis and other skin diseases, asthma and other diseases. Brazilin can prevent, mitigate and / or treat vascular proliferation related diseases like restenosis after PCI, atherosclerosis, high blood pressure, neointima formation after vascular transplantation, vascular diseases after organ transplantation, diabetic angiopathies and the like.

The subject invention provides dipeptides useful in preventing pathological proliferation of blood vessels. The dipeptides of the subject invention are particularly advantageous because they are stable, bioavailable, and can be formulated in an aqueous solution, and in particular, into infant formulations.

The invention provides a dual-target fusion protein, which contains VEGF receptors and cell membrane fragments of PDGF beta receptors. Through the optimized combination of functional fragments, the present invention improves the binding ability of the fusion protein and the dual-target VEGF and PDGF β, can effectively inhibit the proliferation of new blood vessels, and achieve the treatment of neovascular proliferation diseases related to VEGF and PDGF β, such as tumor and wet age-related macular degeneration (AMD).